Form 4: Tarsus Pharmaceuticals Director Equity Grants

David E. Pyott, a Director at Tarsus Pharmaceuticals, received stock options and restricted stock units on June 25, 2026.

Summary

• David E. Pyott, a Director at Tarsus Pharmaceuticals, Inc. (TARS), was granted stock options and restricted stock units (RSUs) on June 25, 2026.
• The stock option grant is for 3,837 shares with an exercise price of $64.34, vesting in full on June 24, 2036, contingent on continued service.
• Additionally, Pyott received 2,417 RSUs that vest in full on the one-year anniversary of the grant date, subject to continuous service.
• A separate grant of 806 RSUs was also awarded, with vesting in equal installments on September 15, 2026, December 15, 2026, March 15, 2027, and June 15, 2027, also contingent on continuous service.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it reports routine equity grants to a director rather than significant financial or strategic developments.

Positives

• Director David E. Pyott received equity awards, indicating continued confidence and alignment with the company's performance.
• The grants are structured to vest over time, incentivizing long-term commitment from the director.
• The stock option exercise price of $64.34 suggests a valuation expectation for the company's stock.

Risks

• Vesting of equity awards is contingent on the director's continuous service, meaning departure from the company would result in forfeiture of unvested awards.
• The stock option exercise price of $64.34 implies that the stock price would need to exceed this level for the options to be profitable.

Future Outlook

The filing does not contain forward-looking statements or guidance regarding the company's financial performance. It solely reports on equity grants to a director.

Industry Context

StockSavvy.ai notes that the issuance of stock options and RSUs to directors is a common practice in the pharmaceutical industry to align executive and director interests with shareholder value and to attract and retain talent.

Stakeholder Impact

• Shareholders: The equity grants align director interests with shareholder value, potentially leading to decisions that benefit the company's stock price.
• Employees: The grants may signal a stable leadership structure, which can positively impact employee morale and confidence.
• Management: The grants reinforce the compensation structure for non-employee directors.

Next Steps

• Director David E. Pyott will continue his service to Tarsus Pharmaceuticals, Inc.
• Vesting of stock options and restricted stock units will occur according to the schedule outlined in the filing, contingent on continued service.

Key Dates

Keywords

Tarsus Pharmaceuticals, TARS, Form 4, SEC Filing, Director Compensation, Stock Options, Restricted Stock Units, Equity Awards, Beneficial Ownership, David E. Pyott